Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. 2019

A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
Center for Cancer Immunology and Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, U.S.A.

UI MeSH Term Description Entries
D008297 Male Males
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322 Antineoplastic Agents, Immunological Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics
D000074324 Ipilimumab An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells. Anti-CTLA-4 MAb Ipilimumab,MDX 010,MDX-010,MDX-CTLA-4,MDX010,Yervoy,Anti CTLA 4 MAb Ipilimumab,Ipilimumab, Anti-CTLA-4 MAb,MDX CTLA 4
D000082082 Immune Checkpoint Inhibitors Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. CTLA-4 Inhibitor,CTLA-4 Inhibitors,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors,Immune Checkpoint Blockade,Immune Checkpoint Blockers,Immune Checkpoint Inhibition,Immune Checkpoint Inhibitor,PD-1 Inhibitor,PD-1 Inhibitors,PD-1-PD-L1 Blockade,PD-L1 Inhibitor,PD-L1 Inhibitors,Programmed Cell Death Protein 1 Inhibitor,Programmed Cell Death Protein 1 Inhibitors,Programmed Death-Ligand 1 Inhibitors,Blockade, PD-1-PD-L1,CTLA 4 Inhibitor,CTLA 4 Inhibitors,Checkpoint Blockade, Immune,Checkpoint Blockers, Immune,Checkpoint Inhibition, Immune,Checkpoint Inhibitor, Immune,Checkpoint Inhibitors, Immune,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors,Inhibitor, PD-1,PD 1 Inhibitor,PD 1 Inhibitors,PD 1 PD L1 Blockade,PD L1 Inhibitor,PD L1 Inhibitors,Programmed Death Ligand 1 Inhibitors
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm

Related Publications

A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 2022, Clinical, cosmetic and investigational dermatology,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 2022, Journal of cutaneous medicine and surgery,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
February 2014, North American journal of medical sciences,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 1989, Acta dermato-venereologica,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
April 2012, Orbit (Amsterdam, Netherlands),
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 1989, Indian journal of dermatology, venereology and leprology,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
September 2022, Acta oncologica (Stockholm, Sweden),
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 2018, Medical science monitor : international medical journal of experimental and clinical research,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
February 1999, Hematology/oncology clinics of North America,
A H Ameri, and M J Mooradian, and K S Emerick, and J C Park, and L J Wirth, and M M Asgari, and H Tsao, and D Lawrence, and R J Sullivan, and S Demehri
January 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society,
Copied contents to your clipboard!